Challenges and opportunities in drug discovery from plants

Current Science

Volumn 92, Issue 9, 2007, Pages 1251-1257

  Jachak, Sanjay M ^a   Saklani, Arvind ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Bioprospecting; Drug discovery; Ethnobotany; Ethnopharmacology; Medicinal plants

Indexed keywords

EID: 34249700741     PISSN: 00113891     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Samuelsson, G., Drugs of Natural Origin: A Textbook of Pharmacognosy, 5th Swedish Pharmaceutical Press, Stockholm, 2004.
2. Kinghorn, A. D., Pharmacognosy in the 21st century. J. Pharm. Pharmacol., 2001, 53, 135-148.
3. Newman, D. J., Cragg, G. M. and Snader, K. M., The influence of natural products upon drug discovery. Nat. Prod. Rep., 2000, 17, 215-234.
4. Butler, M. S., The role of natural product chemistry in drug discovery. J. Nat. Prod., 2004, 67, 2141-2153.
5. Cragg, G. M. and Boyd, M., Drug discovery and development at the National Cancer Institute: the role of natural products of plant origin. In Medicinal Plant Resources of the Tropical Forest (eds Balick, M. J., Elisabetsky, E. and Laird, S. A.), Columbia University Press, New York, 1996, pp. 101-136.
6. Cragg, G. M., Schepartz, S. A., Suffness, M. and Grever, M. R., The taxol supply crisis. New NCI policies for handling the large-scale production of novel natural product anticancer and anti-HIV agents. J. Nat. Prod., 1993, 56, 1657-1668.
7. Baker, J. T. et al., Natural products drug discovery and development: New perspectives on international collaboration. J. Nat. Prod., 1995, 58, 1325-1357.
8. Geysen, H. M., Schoenen, F., Wagner, D. and Wagner, R., Combinatorial compound libraries for drug discovery: An ongoing challenge. Nature Rev. Drug Discov., 2003, 2, 222-230.
9. Lombardino, J. G. and Lowe III, J. A., The role of the medicinal chemist in drug discovery - Then and now. Nature Rev. Drug Discov., 2004, 3, 853-862.
10. Newman, D. J., Cragg, G. M. and Snader, K. M., Natural products as sources of new drugs over the period 1981-2002. J. Nat. Prod., 2003, 66, 1022-1037.
11. van Agtmael, M. A., Eggelte, T. A. and van Boxtel, C. J., Artemisinin drugs in the treatment of malaria: From medicinal herb to registered medication. Trends Pharmacol. Sci., 1999, 20, 199-205.
12. Graul, A. I., The year's new drugs. Drug News Perspect., 2001, 14, 12-31.
13. Heinrich, M. and Teoh, H. L., Galanthamine from snowdrop - The development of modern drug against Alzheimer's disease from local Caucasian knowledge. J. Ethnopharmacol., 2004, 92, 147-162.
14. Prittila, T., Wilcock, G., Truyen, L. and Damaraju, C. V., Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: Multicenter trial. Eur. J. Neurol., 2004, 11, 734-741.
15. Frantz, S., 2004 approvals: The demise of the blockbuster? Nature Rev. Drug Discov., 2005, 4, 93-94.
16. Mundy, C. and Kirkpatrick, P., Tiotropium bromide. Nature Rev. Drug Discov., 2004, 3, 643.
17. Dewick, P. M., Medicinal Natural Products: A Biosynthetic Approach, John Wiley, Chichester, England, 2002, 2nd edn, pp. 297-301.
18. Lotsch, J. and Geisslinger, G., Morphine-6-glucuronide: An analgesic of the future? Clin. Pharmacokinetics, 2001, 40, 485-499.
19. Cragg, G. M. and Newman, D. J., A tale of two tumour targets: Topoisomerase I and tubulin. The Wall and Wani contribution to cancer chemotherapy. J. Nat. Prod., 2004, 67, 232-244.
20. Okouneva, T., Hill, B. T., Wilson, L. and Jordan, M. A., The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics. Mol. Cancer Ther., 2003, 2, 427-436.
21. Butler, M. S., Natural products to drugs: Natural product derived compounds in clinical trials. Nat. Prod. Rep., 2005, 22, 162-195.
22. Kashman, Y. et al., The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum. J. Med. Chem., 1992, 35, 2735-2743.
23. Yu, D., Suzuki, M., Xie, L., Morris-Natschke, S. L. and Lee, K. H., Recent progress in the development of coumarin derivatives as potent anti-HIV agents. Med. Res. Rev., 2003, 22, 322-345.
24. Creagh, T. et al., Safety and pharmacokinetics of single doses of (+)-calanolide A, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects. Antimicrob. Agents Chemother., 2001, 45, 1379-1386.
25. Jachak, S. M. and Jain, R., Current status of target-based antimycobacterial natural products. Anti-Infect. Agents Med. Chem., 2006, 5, 123-133.
26. Sausville, E. A. et al., Cyclin-dependent kinases: Initial approaches to exploit a novel therapeutic target. Pharmacol. Ther., 1999, 82, 285-292.
27. Cragg, G. M. and Newman D. J., Plants as a source of anti-cancer agents. J. Ethnopharmacol., 2005, 100, 72-79.
28. De Souza, N. J., Industrial development of traditional drugs: The forskolin example. J. Ethnopharmacol., 1993, 38, 177-180.
29. Singh, R. B., Niaz, M. A. and Ghosh, S., Hypolipidemic and antioxidant effects of Commiphora mukul as an adjunct to dietary therapy in patients with hypercholesterolaemia. Cardiovasc. Drugs Ther., 1994, 8, 659-664.
30. Urizar, N. L. et al., A natural product that lowers cholesterol as an antagonist ligand for FXR. Science, 2002, 296, 1703-1706.
31. Dickson, M. and Gagnon, J. P., Key factors in the rising cost of new drug discovery and development. Nature Rev. Drug Discov., 2004, 3, 417-429.
32. Koehn, F. E. and Carter, G. T., The evolving role of natural products in drug discovery. Nature Rev. Drug Discov., 2005, 4, 206-220.
33. Rosenthal, J., Curtain has fallen on hopes of legal bioprospecting. Nature, 2002, 416, 15.
34. Soejarto, D. D. et al., The UIC ICBG (University of Illinois at Chicago International Cooperative Biodiversity Group) Memorandum of Agreement: A model of benefit-sharing arrangement in natural product drug discovery and development. J. Nat. Prod., 2004, 67, 294-299.
35. Knowles, J. and Gromo, G., Target selection in drug discovery. Nature Rev. Drug Discov., 2003, 2, 63-69.
36. Kramer, R. and Cohen, D., Functional genomics to new drug targets. Nature Rev. Drug Discov., 2004, 3, 965-972.
37. Walters, W. P. and Namchuk, M., Designing screens: How to make your hits a hit. Nature Rev. Drug Discov., 2003, 2, 259-266.
38. Ley, S. V. and Baxendale, I. R., New tools and concepts for modern organic synthesis. Nature Rev. Drug Discov., 2002, 1, 573-586.
39. Federsel, H. J., Logistics of process R&D: Transforming laboratory methods to manufacturing scale. Nature Rev. Drug Discov., 2003, 2, 654-664.
40. Gurib-Fakim, A., Medicinal plants: Traditions of yesterday and drugs of tomorrow Mol. Aspects Med., 2006, 27, 1-93.
41. Sanjappa, M., Plant diversity in India - Status, conservation and challenges (P. Maheshwari Medal Award Lecture). In XXVIII Conference of Indian Botanical Society, BSI, Dehradun, 24-26 October 2005, pp. 5-6.
42. Prakash, V., Indian medicinal plants: Current status-I. Ethnobotany, 1998, 10, 112-121.
43. http://envfor.nic.in/divisions/biodiv/biodiv/dbdr2003.htm; http://envfor.nic.in/divisions/biodiv/gsr-261(e).html
44. http://whqlibdoc.who.int/publications/2003/9241546271.pdf
45. http://164.100.9.245/exim/2000/not/not98/not298.htm
46. Patwardhan, B., Ethnopharmacology and drug discovery. J. Ethnopharmacol., 2005, 100, 50-52.
47. Soejarto, D. D. et al., Ethnobotany/ethnopharmacology and mass bioprospecting: Issues on intellectual property and benefit-sharing. J. Ethnopharmacol., 2005, 100, 15-22.
48. Saklani, A. and Mukhopadhyay, T., Role of plant extract library in drug discovery. In IUPAC International Conference on Biodiversity and Natural Products: Chemistry and Medical Applications, Univ. of Delhi, 26-31 January 2004, OP-37.
49. Pushpangadan, P. and Nair, K. N., Value addition and commercialization of biodiversity and associated traditional knowledge in the context of the intellectual property regime. J. Intellect. Property Rights, 2005, 10, 441-453.